The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Rheumatology Journal Club #2: Rituximab for AAV Relapse
March 13th 2015In its second Twitter-based discussion, the online rheumatology journal club RheumJC pondered a study that shows rituximab effective for relapse in ANCA-associated vasculitis. The 387 "tweets" are reduced here to 11 easy-to-read slides.
Scientists Identify Mechanism of Action of Potential Psoriasis Therapy
March 12th 2015Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.
New Rheumatoid Arthritis Patient Care Model Leads to Significant Cost Reductions
Rheumatoid arthritis patient care costs can be reduced using the Attribution, Integration, Measurement, Finances and Reporting of Therapies (AIM FARTHER) model developed by researchers at Geisinger Health System in Central Pennsylvania.
Why Does This Male Patient with Rheumatic Heart Disease Have Congestive Heart Failure?
March 11th 2015The patient is a 48-year-old male with "heart trouble" since the age of 6 years, after having rheumatic fever. He was treated with digitalis and diuretics until he was 31 years of age when he was admitted for heart failure and underwent closed commissurotomy.
FDA Approves Neupogen Biosimilar, First in US
March 7th 2015The filgrastim biosimilar Zarxio, the first approved in the US, can be used to treat patients with acute myelogenous leukemia and bone marrow transplants, among other conditions. A biosimilar form of the rheumatology drug infliximab may be close on its heels.
Rheumatology Case Quiz Collection: Fevers, Rashes, Nodules
March 6th 2015Not all cases with rheumatic disease turn up in the rheumatology literature, of course. Test your diagnostic skills on these four puzzlers from other journals. (We present brief descriptions only, with hyperlinks to the original reports.)
Mobilizing Immunotherapy for Type 1 Diabetes: On the Horizon
March 3rd 2015Type 1 diabetes mellitus is an autoimmune disease in which the body destroys all or part of its own roughly 1 billion β cells and cannot regenerate these critical endocrine components. Researchers have turned their attention to immunotherapies for treatment, postulating that targeting the immune system might restore β-cell function. It appears that combination therapies may be needed since clinical trial results have not met expectations based on animal studies.